Q4 2018 EPS Estimates for Integra Lifesciences Holdings Corp (IART) Reduced by Oppenheimer

Integra Lifesciences Holdings Corp (NASDAQ:IART) – Stock analysts at Oppenheimer decreased their Q4 2018 earnings estimates for shares of Integra Lifesciences in a research report issued to clients and investors on Thursday, November 1st. Oppenheimer analyst S. Lichtman now expects that the life sciences company will post earnings per share of $0.62 for the quarter, down from their prior estimate of $0.63. Oppenheimer has a “Buy” rating and a $70.00 price target on the stock.

Other analysts also recently issued reports about the stock. BTIG Research reiterated a “buy” rating and issued a $69.00 price objective on shares of Integra Lifesciences in a research report on Thursday, October 11th. BidaskClub downgraded shares of Integra Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 12th. Cantor Fitzgerald reiterated a “hold” rating and issued a $59.00 price objective on shares of Integra Lifesciences in a research report on Wednesday, July 25th. Morgan Stanley set a $68.00 price objective on shares of Integra Lifesciences and gave the company a “hold” rating in a research report on Thursday, October 11th. Finally, Zacks Investment Research upgraded shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $61.00.

Shares of NASDAQ:IART opened at $53.88 on Monday. The stock has a market capitalization of $4.57 billion, a P/E ratio of 27.77, a PEG ratio of 1.69 and a beta of 0.76. Integra Lifesciences has a fifty-two week low of $45.96 and a fifty-two week high of $67.50. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.08 and a current ratio of 3.20.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.59. The firm had revenue of $365.85 million for the quarter, compared to the consensus estimate of $367.89 million. Integra Lifesciences had a net margin of 5.49% and a return on equity of 16.99%. Integra Lifesciences’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the firm posted $0.45 EPS.

A number of institutional investors have recently added to or reduced their stakes in the business. Zeke Capital Advisors LLC acquired a new position in shares of Integra Lifesciences in the 2nd quarter worth approximately $204,000. We Are One Seven LLC acquired a new position in shares of Integra Lifesciences in the 3rd quarter worth approximately $211,000. Eagle Boston Investment Management Inc. acquired a new position in shares of Integra Lifesciences in the 2nd quarter worth approximately $223,000. World Asset Management Inc acquired a new position in shares of Integra Lifesciences in the 2nd quarter worth approximately $261,000. Finally, Zions Bancorporation acquired a new position in shares of Integra Lifesciences in the 3rd quarter worth approximately $272,000. 84.82% of the stock is currently owned by hedge funds and other institutional investors.

In other Integra Lifesciences news, insider Jeffrey Mosebrook sold 1,000 shares of the firm’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $62.42, for a total transaction of $62,420.00. Following the transaction, the insider now owns 3,085 shares of the company’s stock, valued at approximately $192,565.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Richard E. Caruso sold 46,676 shares of the firm’s stock in a transaction dated Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the transaction, the insider now directly owns 134,134 shares in the company, valued at approximately $8,475,927.46. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,592 shares of company stock worth $3,573,584. 5.10% of the stock is owned by corporate insiders.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: Book Value Per Share – BVPS

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply